NextCure Inc (NXTC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NextCure Inc (NXTC) has a cash flow conversion efficiency ratio of -0.265x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.27 Million) by net assets ($23.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NextCure Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
NextCure Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how NextCure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NextCure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NextCure Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fly Play hf.
IC:PLAY
|
N/A |
|
TME PHARM.CONF.IPO EO 1-
F:0N6A
|
N/A |
|
BAWAT WATER TECHNOLOGIES
F:M5W
|
0.190x |
|
Keybridge Capital Ltd
AU:KBC
|
-0.412x |
|
Diamond Estates Wines & Spirits Inc
V:DWS
|
-0.017x |
|
DB ENERGY S.A. ZY -10
F:0CJ
|
-0.032x |
|
Dynasty Gold Corp
V:DYG
|
0.010x |
|
Pool Advista Indonesia Tbk
JK:POOL
|
0.022x |
Annual Cash Flow Conversion Efficiency for NextCure Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of NextCure Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of NextCure Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $65.47 Million | $-40.80 Million | -0.623x | -34.62% |
| 2023-12-31 | $114.42 Million | $-52.97 Million | -0.463x | -43.94% |
| 2022-12-31 | $167.53 Million | $-53.89 Million | -0.322x | -31.14% |
| 2021-12-31 | $233.39 Million | $-57.24 Million | -0.245x | -60.26% |
| 2020-12-31 | $293.72 Million | $-44.95 Million | -0.153x | -38.12% |
| 2019-12-31 | $321.48 Million | $-35.62 Million | -0.111x | +34.91% |
| 2018-12-31 | $-46.94 Million | $7.99 Million | -0.170x | -133.21% |
| 2017-12-31 | $-24.41 Million | $-12.51 Million | 0.513x | -- |
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leuke… Read more